In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Eisai to market Arena's lorcaserin in the US; Eisai now has global rights

Executive Summary

Arena Pharmaceuticals Inc. (developing therapeutics that target G protein-coupled receptors) has licensed Eisai Inc. (the US subsidiary of Japanese pharmaco Eisai Co. Ltd.) exclusive US marketing rights to its lorcaserin, which is currently pending FDA approval for obesity and weight management.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information

Related Companies

Advertisement
UsernamePublicRestriction

Register